New hope for blood cancer patients: experimental drug enters major trial
NCT ID NCT07255872
Summary
This study is testing a new drug, BL-M11D1, in combination with two different sets of standard chemotherapy drugs for adults newly diagnosed with acute myeloid leukemia (AML). The main goals are to find a safe and effective dose and to see how well the combinations work to control the cancer. It will involve about 216 participants across multiple medical centers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.